Astrana Health (NASDAQ:ASTH) Stock Price Expected to Rise, Truist Financial Analyst Says

Astrana Health (NASDAQ:ASTH) had its target price raised by analysts at Truist Financial from $37.00 to $38.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price would suggest a potential upside of 56.64% from the stock’s current price.

A number of other research firms have also recently issued reports on ASTH. BTIG Research decreased their target price on Astrana Health from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Needham & Company LLC assumed coverage on Astrana Health in a report on Friday, December 12th. They set a “buy” rating and a $28.00 price objective on the stock. Zacks Research upgraded Astrana Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday. Weiss Ratings reissued a “sell (d+)” rating on shares of Astrana Health in a research note on Monday, December 29th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Astrana Health in a report on Tuesday, November 25th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Astrana Health currently has an average rating of “Moderate Buy” and an average price target of $34.00.

Astrana Health Price Performance

ASTH opened at $24.26 on Friday. The company has a debt-to-equity ratio of 1.25, a current ratio of 1.40 and a quick ratio of 1.40. The stock has a market capitalization of $1.37 billion, a P/E ratio of 52.74 and a beta of 0.91. The company’s 50 day simple moving average is $23.46 and its 200-day simple moving average is $25.96. Astrana Health has a one year low of $18.08 and a one year high of $34.80.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Monday, March 2nd. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.39. Astrana Health had a return on equity of 5.59% and a net margin of 0.71%.The firm had revenue of $950.53 million for the quarter, compared to the consensus estimate of $930.46 million. During the same quarter in the prior year, the business earned ($0.15) EPS. The business’s revenue for the quarter was up 42.9% compared to the same quarter last year. Sell-side analysts anticipate that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ASTH. Signaturefd LLC raised its holdings in Astrana Health by 57.9% in the 4th quarter. Signaturefd LLC now owns 1,058 shares of the company’s stock valued at $26,000 after acquiring an additional 388 shares during the period. GAMMA Investing LLC lifted its position in Astrana Health by 144.7% during the fourth quarter. GAMMA Investing LLC now owns 1,473 shares of the company’s stock worth $37,000 after acquiring an additional 871 shares during the last quarter. Strs Ohio bought a new stake in shares of Astrana Health during the fourth quarter worth approximately $40,000. Covestor Ltd grew its position in shares of Astrana Health by 210.6% in the third quarter. Covestor Ltd now owns 3,233 shares of the company’s stock valued at $92,000 after purchasing an additional 2,192 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in shares of Astrana Health by 323.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock valued at $115,000 after purchasing an additional 3,517 shares during the last quarter. 52.77% of the stock is currently owned by institutional investors and hedge funds.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.